Akeso and Summit Therapeutics’ PD-1/VEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination. More: With new trial win, Akeso bispecific shows prior success against Keytruda is no
read moreCEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set drug prices relative to those in the U.S., among other measures. The chief executives argued that the move is
read morePaul Reider has followed Coherus BioSciences’ last biosimilar product out the door. As the biotech completes its pivot from biosimilars to novel immuno-oncology programs, Reider has resigned as chief commercial officer to pursue other opportunities. More: Coherus loses commercial chief
read moreTwo years after leaving the Pharmaceutical Research and Manufacturers of America, AstraZeneca has rejoined the industry trade group. More: 2 years after leaving PhRMA, AstraZeneca opts back in Source: fierce
read more
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine More: Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine Source: News
read moreGalderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow the biologic into a $2 billion product, the company is running ads across national TV and digital
read more© 1994 - 2026 B.M. Pharmaceuticals